Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Yue Zhao

Matched on ORCID iD 0000-0002-9603-8665; OpenAlex author ID A5101631932. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 4 papers

Papers 8

  1. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. Co-author DOI 10.1002/jev2.12484↗
  2. Tumor-associated macrophages drive glycolysis through the IL-8/STAT3/GLUT3 signaling pathway in pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.216784↗
  3. Glycolysis and tumor progression promoted by the m6A writer VIRMA via m6A-dependent upregulation of STRA6 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2024.216840↗
  4. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02880-8↗
  5. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. Co-author DOI 10.1016/j.canlet.2022.215836↗
  6. Arsenic trioxide-loaded nanoparticles enhance the chemosensitivity of gemcitabine in pancreatic cancer via the reversal of pancreatic stellate cell desmoplasia… Co-author DOI 10.1039/d2bm01039a↗
  7. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Co-author DOI 10.1016/j.canlet.2017.09.019↗
  8. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaihong Huang · 5 shared papers, 2022–2024 · strength 0.94
  2. Jinmao Zou · 4 shared papers, 2024 · strength 0.79
  3. Ziyi Zhong · 4 shared papers, 2024 · strength 0.79
  4. Yaqing Li · 4 shared papers, 2022–2024 · strength 0.74
  5. Kege Yang · 4 shared papers, 2022–2024 · strength 0.74
  6. Shurui Zhou · 3 shared papers, 2024 · strength 0.59
  7. Shaojie Chen · 3 shared papers, 2022–2024 · strength 0.55
  8. Jiajia Li · 3 shared papers, 2022–2024 · strength 0.55
  9. Guoda Lian · 3 shared papers, 2022–2024 · strength 0.54
  10. Hanming Yao · 3 shared papers, 2022–2024 · strength 0.54
  11. Yunlong Li · 2 shared papers, 2024 · strength 0.40
  12. Zhiqiang Fu · 3 shared papers, 2017–2022 · strength 0.25
  13. Quanbo Zhou · 3 shared papers, 2017–2022 · strength 0.25
  14. Rufu Chen · 3 shared papers, 2017–2022 · strength 0.25
  15. Xiaohui Zhao · 3 shared papers, 2017–2022 · strength 0.25
  16. Huilin Ye · 3 shared papers, 2017–2022 · strength 0.25
  17. Shangyou Zheng · 3 shared papers, 2017–2022 · strength 0.25
  18. Yuzhou Huang · 1 shared paper, 2024 · strength 0.20
  19. Shaojie Chen · 1 shared paper, 2024 · strength 0.20
  20. Yuzhou Huang · 1 shared paper, 2024 · strength 0.20
  21. Changhao Chen · 2 shared papers, 2017–2022 · strength 0.19
  22. Jiajia Li · 1 shared paper, 2024 · strength 0.19
  23. Shangxiang Chen · 1 shared paper, 2022 · strength 0.15
  24. Lusheng Wei · 1 shared paper, 2017 · strength 0.06
  25. Guolin Li · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.